Pneumocystis jirovecii pneumonia

Pneumocystis jirovecii pneumonia
Name	Pneumocystis jirovecii pneumonia
Symptoms	dyspnea, nonproductive cough, fever
Complications	respiratory failure, pneumothorax
Onset	subacute
Causes	Pneumocystis jirovecii
Risks	immunosuppression, HIV/AIDS, corticosteroids
Diagnosis	chest radiography, computed tomography, bronchoalveolar lavage
Treatment	trimethoprim–sulfamethoxazole, pentamidine, corticosteroids
Prognosis	variable; higher mortality with advanced immunosuppression

Pneumocystis jirovecii pneumonia is an opportunistic fungal pneumonia primarily affecting people with impaired cellular immunity. First characterized in immunocompromised patients during the mid-20th century, it emerged as a major cause of morbidity and mortality among people with acquired immunodeficiency syndrome and in recipients of immunosuppressive therapies. Today it remains clinically important across settings including HIV/AIDS clinics, oncology centers, transplant services, and rheumatology practices.

Introduction

Historically recognized after outbreaks in Europe and North America, the disease gained prominence during the AIDS epidemic and has been a focus of public health responses by organizations such as the World Health Organization and the Centers for Disease Control and Prevention. Clinical management intersects institutions like the National Institutes of Health, academic hospitals including Massachusetts General Hospital and Johns Hopkins Hospital, and specialty societies such as the Infectious Diseases Society of America. Research into pathogenesis and therapy has involved collaborations with universities including Harvard University, Oxford University, and Stanford University.

Etiology and Microbiology

The etiologic agent is a fungal organism historically classified under protozoa and named in honor of the Czech parasitologist Otto Jírovec; taxonomic revisions reflect molecular studies led by laboratories at institutions such as the Pasteur Institute and the Wellcome Trust Sanger Institute. Laboratory methods for organism identification rely on molecular assays developed in research centers like the Broad Institute and reference laboratories at the American Society for Microbiology. The organism shows affinity for alveolar epithelium, with life stages described in histopathology resources used in departments at Mayo Clinic and Cleveland Clinic.

Epidemiology and Risk Factors

Incidence rose sharply during the AIDS epidemic of the 1980s, prompting surveillance by the World Health Organization and guideline development by agencies including the European Centre for Disease Prevention and Control. Key risk factors identified in cohort studies from centers such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute include advanced HIV infection (CD4 counts <200 cells/μL), hematologic malignancies treated at institutions like MD Anderson Cancer Center, solid organ transplantation programs at hospitals such as UCLA Medical Center, and prolonged corticosteroid or immunosuppressant use managed in clinics affiliated with Johns Hopkins University School of Medicine and Mayo Clinic School of Medicine.

Clinical Presentation and Diagnosis

Patients typically present with progressive dyspnea, nonproductive cough, and fever; clinical descriptions appear in textbooks used at Columbia University College of Physicians and Surgeons and University of California, San Francisco School of Medicine. Radiographic patterns, including bilateral interstitial infiltrates on chest radiography and ground-glass opacities on computed tomography, are interpreted in radiology services at institutions like Royal College of Radiologists-affiliated hospitals. Definitive diagnosis often requires bronchoalveolar lavage with identification by immunofluorescence or PCR assays developed in laboratories such as the Centers for Disease Control and Prevention and commercial diagnostics companies. Differential diagnosis involves entities managed by pulmonology services at National Jewish Health and infectious causes investigated at Karolinska Institutet.

Treatment and Management

First-line therapy is trimethoprim–sulfamethoxazole, a regimen recommended in treatment guidelines from the Infectious Diseases Society of America and implemented in clinics including St. Vincent's Hospital and university-affiliated centers like Yale New Haven Hospital. Alternatives such as pentamidine, atovaquone, and clindamycin–primaquine are used based on intolerance or severity, with dosing strategies taught in pharmacology courses at King’s College London and University of Toronto. Adjunctive corticosteroids are indicated for moderate-to-severe hypoxemia per protocols used in intensive care units at Royal Brompton Hospital and University College London Hospitals. Management also involves respiratory support modalities used in critical care units at Addenbrooke's Hospital and Mount Sinai Hospital.

Prevention and Prognosis

Primary prophylaxis with trimethoprim–sulfamethoxazole is recommended for high-risk populations identified by HIV clinics such as those at Brown University-affiliated clinics and transplant programs at Northwestern Memorial Hospital, reflecting guidelines from the World Health Organization and the Centers for Disease Control and Prevention. Vaccination strategies do not target this pathogen; prevention focuses on screening, prophylaxis, and prompt antiretroviral therapy delivered through programs like the President's Emergency Plan for AIDS Relief and national HIV treatment initiatives in countries such as South Africa and Brazil. Prognosis has improved with antiretroviral therapy rollouts championed by organizations including Médecins Sans Frontières and research networks like the International AIDS Society, though mortality remains elevated in patients with delayed diagnosis or advanced immunosuppression treated at resource-limited hospitals in regions represented by the World Bank and Global Fund.

Category:Fungal respiratory diseases